Patients New Evidation CEO to double down on patient data empowerment pharmaphorum spoke with Leslie Olay Wilberforce, Evidation's new CEO, about the company's unique approach to real-world data and her future plans.
Patients From trauma to healing: How therapy complements medication i... Trauma therapy is more than just talk – it’s an evidence-backed process that helps patients reframe, process, and recover from life-altering events.
Patients On patient-centric treatment decisions and the value of quan... Marc Buyse, founder of IDDI and One2Treat, and also co-founder of CluePoints, discusses the pressing need for quantitative methodologies.
Patients Innovation without access is just a headline: Closing the ga... More than 4.5 billion people - over half the world’s population - lack full coverage of essential health services.
Patients The unexpected starting line: Solving drug affordability at ... In early 2025, the White House renewed its push to lower prescription drug prices, part of an executive order aimed at easing patients' financial burdens.
Patients BIO 2025: Planning, not panic, as BIO weighs in on US vaccin... At BIO 2025, vaccines were top of mind as a result of recent actions by HHS. Speakers addressed news head on, but also explored the larger context.
News Just how radical is the FDA's complete response letter move? The FDA says publishing complete response letters for medicines is an act of "radical transparency," but it is not as revolutionary as it seems.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face